A5061920107- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Eosinophilic Esophagitis
- Allergic Rhinitis and Sensitization
- Urticaria and Related Conditions
- Contact Dermatitis and Allergies
- Food Allergy and Anaphylaxis Research
- Eosinophilic Disorders and Syndromes
- Vasculitis and related conditions
- Mast cells and histamine
- Sinusitis and nasal conditions
University of Palermo
2023-2024
University of Messina
2018-2022
Institute for Biomedical Research and Innovation
2021
National Research Council
2021
The efficacy of dupilumab as biological treatment severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit the pathophysiologic mechanisms involved in type 2 inflammation.
Abstract Background and Objective Several randomized controlled trials (RCTs) have shown that benralizumab is characterized by a good profile of efficacy safety, thereby being potentially able to elicit clinical remission on‐treatment severe eosinophilic asthma (SEA). The main goal this multicentre observational study was verify the effectiveness in inducing sustained SEA patients with or without comorbid chronic rhinosinusitis nasal polyps (CRSwNP). Methods Throughout 2 years treatment...
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood tissue eosinophilia. Objective To assess the effectiveness safety of mepolizumab (anti-IL-5) benralizumab (anti-IL-5Rα) in EGPA for 24 months. Methods We conducted multicenter observational study, including patients treated anti-IL-5/Rα biologics 9 Italian specialized facilities. Systemic disease activity, remission relapse rate were evaluated from...
BackgroundBiological therapies, such as mepolizumab, have transformed the treatment of severe eosinophilic asthma. Although mepolizumab's short-term effectiveness is established, there limited evidence on its ability to achieve long-term clinical remission.ObjectiveTo evaluate and safety explore potential induce sustained remission, identify baseline factors associated with likelihood achieving remission over 24 months.MethodsThe REMIssion in Severe Eosinophilic Asthma Treated Mepolizumab...
Background The current definition of severe eosinophilic asthma (SEA) super-responders to biologic treatment does not include patients with other eosinophil-based comorbidities. Although granulomatosis polyangiitis (EGPA) is frequently associated SEA, we lack data on a possible super-response treatments in suffering from these two diseases. We aim assess super-responder features real-life SEA and EGPA treated mepolizumab benralizumab. Methods enrolled 39 eligible for or Super-responder...
Mepolizumab and benralizumab are monoclonal antibodies directed against anti-IL-5 anti-IL5R, respectively, their use reduces the exacerbation rate maintains oral corticosteroid requirements in severe eosinophilic asthma. Previous studies have tested therapeutic switch between two biologics with excellent results, further demonstrating heterogeneity of asthmatic disease complexity choice. It remains unclear if such patients may improve following a from mepolizumab to benralizumab. Within...
ABSTRACT Background Biological therapies, such as mepolizumab, have transformed the treatment of severe eosinophilic asthma. While mepolizumab’s short-term effectiveness is established, there limited evidence on its ability to achieve long-term clinical remission. Objective To evaluate and safety explore potential induce sustained remission, identify baseline factors associated with likelihood achieving remission over 24 months. Methods The REMI-M a retrospective, real-world, multicenter...
Hymenoptera sting reactions are among life-threatening causes of allergy. Several epidemiology studies have assessed the risk these kind reactions, general population, around 3% adults. This incidence increases highly at populations such as outdoor workers. stings forestry workers (FW) occupational triggers but it has not yet been well defined which is real anaphylaxis in workers, even Italy. Two Italian reported on hymenoptera (HS) northern Italy (NI) and central (CI) FW while no data...
Biological therapies used for severe asthma may be useful even middle-aged or older patients who have a history of allergic with chronic obstructive pulmonary disease (COPD) overlap phenotype.To show omalizumab efficacy in asthma-COPD disease.Material and methods: We report our data retrospective study on 11 (mean age: 67.18 years) positive treated omalizumab. They all presented limited reversibility airway obstruction signs bronchitis at radiological examinations, as overlap. Omalizumab...
Omalizumab is the best treatment for patients with chronic spontaneous urticaria (CSU). Machine learning (ML) approaches can be used to predict response therapy and effectiveness of a treatment. No studies are available on use ML techniques in CSU.Data from 132 CSU outpatients were analyzed. Urticaria Activity Score over 7 days (UAS7) efficacy assessed. Clinical demographic characteristics training validating models Two methodologies label data based (UAS7 ≥ 6): (A) at 1, 3 5 months; (B)...
<b>Background</b>: The efficacy of dupilumab as treatment severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) depends on its ability to inhibit type 2 inflammation. <b>Methods</b>: We assessed the impact in asthmatic patients, regard skin prick test (SPT) CRSwNP. Clinical, functional, laboratory parameters were measured at baseline 24 weeks after first administration. <b>Results</b>: Among 127 recruited patients asthma, 90 (70.9%) had positive SPT, while 78 (61.4%) complained...
<b>Introduction:</b> Current definition of Severe Eosinophilic Asthma (SEA) Super-Responders (SR) to biologic treatment does not include patients with other eosinophils-based comorbidities. Whereas Granulomatosis Polyangitis (EGPA) is frequently associated SEA, we lack data on a possible super-response treatments in suffering from these two diseases. <b>Aims and Objectives:</b> To assess SR features real-life SEA EGPA treated Mepolizumab Benralizumab. <b>Methods:</b> We enrolled 39 eligible...
<b>Background</b>: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, blood and tissue eosinophilia. <b>Aim</b>: To assess the effectiveness safety of mepolizumab (anti-IL-5) benralizumab (anti-IL-5Rα) in patients EGPA for 24 months. <b>Material Methods</b>: We conducted multicenter observational study, including 49 (31 females, 63.3%) treated anti-IL-5/Rα biologics at 9 Italian outpatients' facilities. Remission rates...